New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever
- Details
- Category: AstraZeneca
New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma.(1) These results are published in the New England Journal of Medicine and are being presented at the American Thoracic Society 2019 International Conference.(1)
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
- Details
- Category: Novartis
Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate, glycopyrronium bromide and mometasone furoate, delivered with the dose-confirming Breezhaler® inhalation device, was presented at the 2019 annual international congress of the American Thoracic Society (ATS).
Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from the Phase I/II STARTRK-NG study, evaluating the investigational medicine entrectinib in children and adolescents with recurrent or refractory solid tumours with and without neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kinase (ALK) gene fusions.
Award-winning actor and producer Sterling K. Brown joins Bristol-Myers Squibb in effort to share stories of What It's Like to Live with Cancer Today
- Details
- Category: Bristol-Myers Squibb
Two-time Emmy Award winner Sterling K. Brown (This Is Us, Black Panther) is partnering with Bristol-Myers Squibb on a series designed to illuminate the triumphs and challenges of life after a cancer diagnosis. Survivorship Today: What It's Like to Live with Cancer explores the stories of people who have experienced lasting physical, emotional and social effects from cancer to build greater understanding of, and draw attention to, survivorship-related issues.
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
- Details
- Category: Novartis
Novartis has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets associated with Xiidra® (lifitegrast ophthalmic solution) 5% worldwide. Xiidra is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease[1].
Boehringer Ingelheim announces finalists of the Making More Health Accelerator Program
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim, one of the world's leading pharmaceutical companies, recently announced to support two projects of its Making More Health Accelerator Program: Melissa Menke, CEO of Access Ayfa and Joost van Engen, CEO of Healthy Entrepreneurs.
Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer
- Details
- Category: AstraZeneca
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201). The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine.
More Pharma News ...
- Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians
- Amgen and Syapse enter precision medicine collaboration in oncology
- Amgen ignites a social fitness movement to support the fight against heart disease and cancer
- AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery
- Bristol-Myers Squibb reports first quarter financial results
- Pfizer and Lilly announce top-line results from long-term Phase 3 study of tanezumab in patients with osteoarthritis
- Roche reports a strong start in 2019 and raises the outlook for the full-year